Armata Pharmaceuticals (TG1N) Income Statement
Armata Pharmaceuticals Income Statement
Last quarter (Q2 2026), Armata Pharmaceuticals's total revenue was $2.51M, an increase of 15.72% from the same quarter last year. In Q2, Armata Pharmaceuticals's net income was $74.14M. See Armata Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 4.90M | $ 5.17M | $ 4.53M | $ 5.51M | $ 4.47M | |
| $ 3.37M | $ -29.25M | $ 3.56M | $ -29.51M | $ -15.54M | |
| $ 34.59M | $ 13.18M | $ 44.45M | $ 7.44M | $ 8.28M | |
| Depreciation and Amortization | $ 1.53M | $ 1.32M | $ 972.00K | $ 892.00K | $ 1.17M |
| $ -155.68M | $ -6.85M | $ -65.45M | $ -36.00M | $ -21.92M | |
| $ -31.22M | $ -42.44M | $ -40.89M | $ -36.95M | $ -23.82M | |
| $ -142.58M | $ 23.52M | $ -28.16M | $ 29.00K | $ 667.00K | |
| $ -173.80M | $ -18.92M | $ -69.05M | $ -36.92M | $ -23.16M | |
| $ -173.80M | $ -18.92M | $ -69.05M | $ -36.92M | $ -23.16M | |
| Per Share Metrics | |||||
| Basic EPS | $ -4.80 | $ -0.52 | $ -1.91 | $ -1.08 | $ -0.96 |
| Diluted EPS | $ -4.80 | $ -0.52 | $ -1.91 | $ -1.08 | $ -0.96 |
| Weighted Average Shares Outstanding | 36.24M | 36.16M | 36.08M | 34.29M | 24.10M |
| Weighted Average Shares Outstanding (Diluted) | 36.24M | 36.16M | 36.08M | 34.29M | 24.10M |
Currency in USD
